The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Researchers have detailed the precise mechanism through which the inflammatory signaling molecule IL-12 contributes to Alzheimer's disease.

Microglia, the brain's immune cells, usually serve as diligent guardians. They eliminate intruders such as microbes and clear ...

When interleukin-12 is added to the cell culture, it leads to a significant reduction in nerve fibers (pink) and oligodendrocytes, and thus to a decline in myelin (white).

While some continue to function effectively, others gradually lose their protective role and start secreting small amounts of inflammatory messengers. One such messenger is interleukin-12 (IL-12).

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

During this mission, the team will grow Janus base nanotubes that carry interleukin-12. Interleukin-12 is a protein already produced naturally by the human body, but only in small quantities. It ...

GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of $2.19bn in 2030.